Free Trial
→ Trump to redistribute trillions of dollars (From Porter & Company) (Ad) Buy LEGN Stock  Free LEGN Stock Alerts

Legend Biotech (LEGN) Financials

Legend Biotech logo
$33.74 +1.63 (+5.08%)
Closing price 04:00 PM Eastern
Extended Trading
$33.59 -0.15 (-0.44%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Legend Biotech

Annual Income Statements for Legend Biotech

This table shows Legend Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -2.78 -102 -266 -404 -446 -518 -177
Consolidated Net Income / (Loss)		 -2.78 -102 -266 -404 -446 -518 -177
Net Income / (Loss) Continuing Operations		 -2.78 -102 -266 -404 -446 -518 -177
Total Pre-Tax Income 		-1.62 -127 -308 -407 -446 -520 -158
Total Operating Income		 -1.53 -135 -234 -403 -479 -471 -331
Total Gross Profit		 63 60 70 60 31 47 371
Total Revenue		 63 60 75 69 117 285 627
Operating Revenue		 63 60 75 69 117 285 627
Total Cost of Revenue		 0.00 0.22 4.56 9.13 86 238 256
Operating Cost of Revenue		 0.00 0.22 4.56 9.13 86 238 256
Total Operating Expenses		 65 194 305 463 510 517 702
Selling, General & Admin Expense		 3.93 32 73 150 174 107 284
Research & Development Expense		 61 162 232 313 336 382 414
Impairment Charge		 - - - - 0.00 0.00 4.42
Total Other Income / (Expense), net		 -0.08 7.24 -74 -7.10 33 -49 173
Other Income / (Expense), net		 -0.08 7.24 6.12 -7.10 33 -49 173
Income Tax Expense		 1.17 -26 -42 -3.61 0.63 -1.86 19
Weighted Average Basic Shares Outstanding		 - - 266.01M 308.46M 330.13M 363.82M 367.30M
Diluted Earnings per Share		 ($0.01) ($0.51) ($1.13) ($1.43) ($1.40) - ($0.48)
Weighted Average Diluted Shares Outstanding		 - - 266.01M 308.46M 330.13M 363.82M 367.30M
Weighted Average Basic & Diluted Shares Outstanding		 - - 266.01M 308.46M 330.13M 363.82M 367.30M

Quarterly Income Statements for Legend Biotech

No quarterly income statements for Legend Biotech are available.

Annual Cash Flow Statements for Legend Biotech

This table details how cash moves in and out of Legend Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 208 -127 372 233 821 5,408 -989
Net Cash From Operating Activities		 308 -83 -223 8.38 433 4,787 -935
Net Cash From Continuing Operating Activities		 217 -79 -280 8.38 433 4,787 -935
Net Income / (Loss) Continuing Operations		 -1.62 -127 -308 0.00 0.00 0.00 0.00
Depreciation Expense		 1.67 5.20 9.74 13 10 11 21
Amortization Expense		 0.02 0.06 0.19 1.38 2.48 1.92 1.93
Non-Cash Adjustments To Reconcile Net Income		 197 3.61 35 -142 420 4,775 -1,107
Changes in Operating Assets and Liabilities, net		 20 40 -16 137 -0.16 -0.18 149
Net Cash From Investing Activities		 -102 -59 -24 -42 1.25 8.81 -14
Net Cash From Continuing Investing Activities		 -96 23 -30 -42 1.25 8.81 -14
Purchase of Property, Plant & Equipment		 -21 -27 -26 -42 - - -14
Net Cash From Financing Activities		 2.50 15 619 323 378 584 0.00
Net Cash From Continuing Financing Activities		 2.50 15 609 323 378 584 0.00
Issuance of Debt		 36 42 - 0.00 378 349 0.00
Issuance of Common Equity		 0.00 0.00 450 323 0.00 234 0.00
Cash Interest Received		 - - - 0.65 5.58 47 37
Cash Income Taxes Paid		 - - - 0.00 - - 1.55

Quarterly Cash Flow Statements for Legend Biotech

No quarterly cash flow statements for Legend Biotech are available.

Annual Balance Sheets for Legend Biotech

This table presents Legend Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 293 722 1,119 1,331 1,849 1,670
Total Current Assets		 115 532 950 1,099 1,498 1,284
Cash & Equivalents		 83 456 689 786 1,278 287
Short-Term Investments		 - - 0.00 186 0.66 0.00
Accounts Receivable		 30 75 50 0.09 100 6.29
Inventories, net		 1.16 1.80 1.75 10 19 24
Prepaid Expenses		 - - 14 62 69 131
Plant, Property, & Equipment, net		 45 72 103 105 109 99
Plant, Property & Equipment, gross		 - - 103 105 109 99
Total Noncurrent Assets		 133 117 48 60 86 110
Intangible Assets		 0.52 2.85 4.68 3.41 4.06 2.16
Other Noncurrent Operating Assets		 132 114 43 57 82 108
Total Liabilities & Shareholders' Equity		 444 1,320 1,119 1,331 1,849 1,670
Total Liabilities		 141 124 354 587 597 630
Total Current Liabilities		 94 116 229 298 216 278
Accounts Payable		 9.59 5.24 7.04 33 31 39
Other Taxes Payable		 - - - 9.77 7.20 21
Other Current Liabilities		 72 102 89 71 56 52
Total Noncurrent Liabilities		 47 8.76 124 289 381 352
Long-Term Debt		 - - 120 261 281 301
Capital Lease Obligations		 - - 1.59 20 44 45
Other Noncurrent Operating Liabilities		 5.06 4.51 0.40 0.23 48 0.00
Total Equity & Noncontrolling Interests		 303 1,196 766 744 1,251 1,041
Total Preferred & Common Equity		 303 1,196 766 744 1,251 1,041
Total Common Equity		 303 1,196 766 744 1,251 1,041
Common Stock		 0.02 0.03 0.03 0.03 0.04 0.04
Other Equity Adjustments		 303 1,196 766 744 1,251 1,041

Quarterly Balance Sheets for Legend Biotech

No quarterly balance sheets for Legend Biotech are available.

Annual Metrics and Ratios for Legend Biotech

This table displays calculated financial ratios and metrics derived from Legend Biotech's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% -4.85% 25.04% -8.23% 70.00% 143.70% 119.97%
EBITDA Growth		 0.00% -182,274.63% -78.91% -81.50% -9.27% -17.18% 73.44%
EBIT Growth		 0.00% -7,778.65% -79.31% -79.70% -8.65% -16.69% 69.60%
NOPAT Growth		 0.00% -8,671.51% -74.22% -71.98% -18.73% 1.67% 29.63%
Net Income Growth		 0.00% -3,549.07% -162.20% -51.51% -10.60% -16.11% 65.84%
EPS Growth		 0.00% -5,000.00% -121.57% -26.55% 2.10% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -127.00% -168.47% 103.76% 5,066.28% 1,005.72% -119.53%
Free Cash Flow Firm Growth		 0.00% 0.00% -46.91% -5.25% -38.97% -28.27% 44.15%
Invested Capital Growth		 0.00% 0.00% 109.07% -22.16% 12.07% 94.75% 7.36%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 99.63% 93.93% 86.73% 26.51% 16.40% 59.15%
EBITDA Margin		 0.11% -203.50% -291.16% -575.86% -370.13% -177.98% -21.49%
Operating Margin		 -2.43% -224.33% -312.56% -585.76% -409.10% -165.08% -52.81%
EBIT Margin		 -2.56% -212.27% -304.40% -596.08% -380.94% -182.41% -25.21%
Profit (Net Income) Margin		 -4.42% -169.37% -355.16% -586.38% -381.48% -181.75% -28.22%
Tax Burden Percent		 172.28% 79.79% 86.40% 99.11% 100.14% 99.64% 111.95%
Interest Burden Percent		 100.00% 100.00% 135.03% 99.25% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -277.19% -156.25% -223.38% -285.74% -180.39% -92.65%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -270.88% -140.37% -209.17% -268.29% -157.23% -98.77%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 210.06% 120.69% 182.23% 226.63% 128.45% 77.20%
Return on Equity (ROE)		 0.00% -67.13% -35.56% -41.15% -59.11% -51.94% -15.45%
Cash Return on Invested Capital (CROIC)		 0.00% -477.19% -226.83% -198.45% -297.12% -244.68% -99.74%
Operating Return on Assets (OROA)		 0.00% -43.51% -45.00% -44.56% -36.38% -32.72% -8.99%
Return on Assets (ROA)		 0.00% -34.72% -52.50% -43.83% -36.43% -32.60% -10.06%
Return on Common Equity (ROCE)		 0.00% -67.13% -35.56% -41.15% -59.11% -51.94% -15.45%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -33.57% -22.28% -52.69% -59.97% -41.41% -17.01%
Net Operating Profit after Tax (NOPAT)		 -1.07 -94 -164 -282 -335 -329 -232
NOPAT Margin		 -1.70% -157.03% -218.79% -410.03% -286.37% -115.55% -36.96%
Net Nonoperating Expense Percent (NNEP)		 0.00% -6.31% -15.88% -14.21% -17.45% -23.16% 6.12%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -32.68% -20.90% -16.72%
Cost of Revenue to Revenue		 0.00% 0.37% 6.07% 13.27% 73.49% 83.60% 40.85%
SG&A Expenses to Revenue		 6.23% 53.97% 96.94% 217.22% 148.75% 37.44% 45.32%
R&D to Revenue		 96.20% 270.00% 309.55% 455.27% 286.87% 134.04% 65.93%
Operating Expenses to Revenue		 102.43% 323.96% 406.49% 672.49% 435.62% 181.48% 111.96%
Earnings before Interest and Taxes (EBIT)		 -1.62 -127 -228 -410 -446 -520 -158
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.07 -122 -218 -396 -433 -507 -135
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 1.40 0.43 8.09 10.34 7.94 5.69
Price to Tangible Book Value (P/TBV)		 0.00 1.40 0.44 8.14 10.39 7.96 5.70
Price to Revenue (P/Rev)		 6.72 7.07 6.92 90.07 65.80 34.83 9.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 5.01 0.44 50.93 56.55 37.20 23.07
Enterprise Value to Revenue (EV/Rev)		 0.00 5.68 0.84 81.84 59.90 31.49 9.53
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 672.13 16.19 1.88 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.16 0.38 0.26 0.33
Long-Term Debt to Equity		 0.00 0.00 0.00 0.16 0.38 0.26 0.33
Financial Leverage		 0.00 -0.78 -0.86 -0.87 -0.84 -0.82 -0.78
Leverage Ratio		 0.00 0.97 0.68 0.94 1.62 1.59 1.54
Compound Leverage Factor		 0.00 0.97 0.91 0.93 1.62 1.59 1.54
Debt to Total Capital		 0.00% 0.00% 0.00% 13.74% 27.40% 20.64% 24.94%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 13.74% 27.40% 20.64% 24.94%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 86.26% 72.60% 79.36% 75.06%
Debt to EBITDA		 0.00 0.00 0.00 -0.31 -0.65 -0.64 -2.57
Net Debt to EBITDA		 0.00 0.00 0.00 1.43 1.59 1.88 -0.44
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.31 -0.65 -0.64 -2.57
Debt to NOPAT		 0.00 0.00 0.00 -0.43 -0.84 -0.99 -1.49
Net Debt to NOPAT		 0.00 0.00 0.00 2.01 2.06 2.89 -0.25
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.43 -0.84 -0.99 -1.49
Altman Z-Score		 0.00 0.65 2.26 10.15 7.58 10.04 6.43
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 1.22 4.61 4.14 3.69 6.92 4.62
Quick Ratio		 0.00 1.20 4.59 3.23 3.26 6.37 1.06
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -162 -238 -251 -348 -447 -250
Operating Cash Flow to CapEx		 1,469.49% -305.02% -849.45% 19.86% 0.00% 0.00% -6,627.25%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.21 0.15 0.07 0.10 0.18 0.36
Accounts Receivable Turnover		 0.00 2.00 1.43 1.10 4.63 5.70 11.80
Inventory Turnover		 0.00 0.19 3.08 5.15 14.21 16.01 11.83
Fixed Asset Turnover		 0.00 1.33 1.28 0.79 1.13 2.67 6.03
Accounts Payable Turnover		 0.00 0.02 0.61 1.49 4.31 7.50 7.40
Days Sales Outstanding (DSO)		 0.00 182.56 255.50 332.54 78.77 64.09 30.94
Days Inventory Outstanding (DIO)		 0.00 1,910.88 118.47 70.93 25.69 22.81 30.87
Days Payable Outstanding (DPO)		 0.00 15,832.08 593.94 245.43 84.77 48.65 49.32
Cash Conversion Cycle (CCC)		 0.00 -13,738.64 -219.96 158.03 19.69 38.24 12.48
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 68 142 111 124 241 259
Invested Capital Turnover		 0.00 1.77 0.71 0.54 1.00 1.56 2.51
Increase / (Decrease) in Invested Capital		 0.00 68 74 -31 13 117 18
Enterprise Value (EV)		 0.00 340 63 5,632 7,008 8,979 5,978
Market Capitalization		 424 424 519 6,199 7,699 9,932 5,919
Book Value per Share		 $0.00 $16.43 $4.49 $2.88 $2.41 $3.79 $2.86
Tangible Book Value per Share		 $0.00 $16.40 $4.48 $2.86 $2.40 $3.78 $2.85
Total Capital		 0.00 303 1,196 888 1,025 1,577 1,386
Total Debt		 0.00 0.00 0.00 122 281 325 346
Total Long-Term Debt		 0.00 0.00 0.00 122 281 325 346
Net Debt		 0.00 -83 -456 -567 -691 -953 59
Capital Expenditures (CapEx)		 21 27 26 42 0.00 0.00 14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -63 -39 32 -170 3.01 720
Debt-free Net Working Capital (DFNWC)		 0.00 20 417 721 801 1,281 1,006
Net Working Capital (NWC)		 0.00 20 417 721 801 1,281 1,006
Net Nonoperating Expense (NNE)		 1.71 7.40 102 121 111 189 -55
Net Nonoperating Obligations (NNO)		 0.00 -235 -1,053 -655 -620 -1,010 -781
Total Depreciation and Amortization (D&A)		 1.68 5.26 9.93 14 13 13 23
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -105.19% -51.69% 46.07% -145.55% 1.05% 114.71%
Debt-free Net Working Capital to Revenue		 0.00% 33.80% 555.90% 1,047.05% 684.87% 449.38% 160.43%
Net Working Capital to Revenue		 0.00% 33.80% 555.90% 1,047.05% 684.87% 449.38% 160.43%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 266.01M 0.00 330.13M 363.82M 367.30M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 266.01M 0.00 330.13M 363.82M 367.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 266.01M 0.00 330.13M 363.82M 367.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.07 -94 -164 -282 -335 -329 -229
Normalized NOPAT Margin		 -1.70% -157.03% -218.79% -410.03% -286.37% -115.55% -36.47%
Pre Tax Income Margin		 -2.56% -212.27% -411.05% -591.63% -380.94% -182.41% -25.21%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Legend Biotech

No quarterly metrics and ratios for Legend Biotech are available.

Frequently Asked Questions About Legend Biotech's Financials

When does Legend Biotech's fiscal year end?

According to the most recent income statement we have on file, Legend Biotech's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Legend Biotech's net income changed over the last 6 years?

Legend Biotech's net income appears to be on an upward trend, with a most recent value of -$177.03 million in 2024, rising from -$2.78 million in 2018. The previous period was -$518.25 million in 2023.

What is Legend Biotech's operating income?
Legend Biotech's total operating income in 2024 was -$331.23 million, based on the following breakdown:
  • Total Gross Profit: $371.01 million
  • Total Operating Expenses: $702.23 million
How has Legend Biotech revenue changed over the last 6 years?

Over the last 6 years, Legend Biotech's total revenue changed from $63.03 million in 2018 to $627.24 million in 2024, a change of 895.1%.

How much debt does Legend Biotech have?

Legend Biotech's total liabilities were at $629.61 million at the end of 2024, a 5.4% increase from 2023, and a 345.6% increase since 2019.

How much cash does Legend Biotech have?

In the past 5 years, Legend Biotech's cash and equivalents has ranged from $83.36 million in 2019 to $1.28 billion in 2023, and is currently $286.75 million as of their latest financial filing in 2024.

How has Legend Biotech's book value per share changed over the last 6 years?

Over the last 6 years, Legend Biotech's book value per share changed from 0.00 in 2018 to 2.86 in 2024, a change of 286.0%.

Remove Ads

Related Companies

This page (NASDAQ:LEGN) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...
Colonial Metals | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
America’s Retirement Accounts Are at Risk—Here’s Why
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored